Selvita S.A. Stock: price and insider trades · Poland

Selvita S.A.: what insiders have been doing

Selvita S.A. has a thin disclosure history in our data (latest filing: 25 November 2025). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by KNF. They describe what insiders did and are not a recommendation.

Insider Decl.

Thresholds

n/a

Buy Volume

n/a

Sell Volume

n/a

Analyst consensus: bullish or bearish?

Analysts rate Selvita S.A. Buy (bullish), based on 6 analysts. Average price target: PLN 35.85.

Fundamental score

Ranked 11,377 of 26,286 companies

55.0

score / 100

Value

Quality

FCF yld19%

Earn yld0.2%

EV/EBITDA8.2x

ROE-0.7%

Gross mgn81%

Net mgn0.2%

Debt/EBITDA2.7x

Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

PLN 18.90

Analyst consensus

6 analysts

Buy

PLN 25.00Target PLN 35.85(+90%)PLN 47.10

Income statement

RevenuePLN 364.2M

Gross profitPLN 293.4M81% margin

EBITDAPLN 62.7M17% margin

Net incomePLN 813k-0.6% margin

Valuation

PER (forward)25.3x

P/Book1.1x

Beta0.10

Balance sheet & cash

Market capPLN 346.8M

Total debtPLN 169.6M

Free Cash FlowPLN 66.1M

Debt / Equity54%

Profitability & ownership

ROE-0.7%

ROA0.9%

% insiders21.2%

% institutions27.3%

Last declaration on 25 November 2025

Declarations1 total

●

Executives

Executives24 Nov 2025

106M PLN0KNF

1 of 1 declaration

About Selvita S.A.

Selvita S.A. is a biotechnology company based in Poland, specializing in the research and development of pharmaceuticals. It focuses on innovative solutions for the treatment of cancer and neurological diseases.